Introduction
In response to DNA damage, cells activate a complex signaling cascade to prevent further cell cycle progression (1) . Activation of this signaling pathway, which is commonly referred to as the DNA damage response (DDR), allows time for DNA repair, or, if the lesions are beyond repair capacity, leads to the induction of apoptosis (1) . Mammalian cells have evolved at least five partially overlapping DNA repair pathways to correct various types of genotoxic lesions -mismatch repair (MMR), nucleotide-excision repair (NER), base-excision repair (BER), homologous recombination (HR) and non-homologous end joining (NHEJ) (2) . MMR removes nucleotides that were mispaired during replication, as well as insertion-and deletion loops, which result from slippage during replication of repetitive sequences. The NER pathway is employed to repair helix-distorting lesions, while small chemical modifications of bases are removed by the BER machinery (2) .
Specifically in response to DNA double-strand breaks (DSBs), mammalian cells employ two distinct repair pathways. NHEJ is an error-prone pathway that is preferentially used during early phases of the cell cycle, when no sister chromatid is available (3) . During NHEJ, the non-catalytic subunits Ku70 and Ku80 form a heterodimer that binds to the free DNA ends and subsequently recruits the catalytic subunit DNA-PKcs (encoded by PRKDC). DNA-PKcs kinase activity is essential for XRCC4-and Lig4-mediated rejoining of the broken DNA ends during NHEJ (4) . HR, the second major DSB repair pathway, is largely restricted to the S-and G 2 -phases of the cell cycle, when a sister chromatid is available to serve as an intact template for DSB repair (5) .
One of the early events, necessary for completion of the HR process, is DSB -5 -end resection to create a single-stranded 3ƍ-overhang, which becomes rapidly coated with RPA and provides a substrate for activation of the proximal DDR kinase ATR (6) . During the ensuing steps of the HR process, RPA is replaced by Rad51, which is recruited to single-stranded DNA (ssDNA) in a Brca1/Brca2/Palb2-dependent fashion (7) . Once loaded onto ssDNA, Rad51 mediates the core reactions of the HR process, namely homology searching, strand exchange, and Holliday junction formation (5) .
The HR pathway is indispensable for the maintenance of genomic integrity and patients with heterozygous germline mutations in different HR-genes display a massively increased risk for the development of cancer (7) . Most notably, germline mutations in BRCA1, BRCA2 and RAD51C are associated with predisposition to breast and ovarian cancer (8, 9) . Furthermore, numerous HR genes, including BRCA1, BRCA2, ATM, CHEK2, RAD50, RAD51C and others, are recurrently somatically mutated in various different cancer entities (7) .
Intriguingly, HR-deficiency in BRCA1-or BRCA2-defective cells and tumors was recently shown to represent an actionable alteration in cancer.
Specifically, a series of recent studies reported a synthetic lethal interaction between Poly(ADP-ribose) polymerase (PARP1) and the high-penetrance breast and ovarian cancer susceptibility genes BRCA1 and BRCA2 (10, 11 ).
In addition, we and others have recently identified a druggable synthetic lethal interaction between the HR gene ATM and the NEHJ kinase gene PRKDC (12) (13) (14) . Here, we propose that it is the HR defect that is responsible for the robust non-oncogene addiction to DNA-PKcs that we had previously observed in ATM-mutant cells and tumors (14) . Thus, the aim of this study was to Furthermore, we functionally confirmed the most striking associations that we identified in high-throughput screening and deciphered mechanisms, which might rationalize these effects. Finally, we provide a detailed examination of our novel therapeutic strategies in vivo.
Results

Activity Profile of KU60648 in a large panel of genomically-annotated cancer cell lines
In order to identify genomic aberrations that are associated with nononcogene addiction to the NHEJ kinase DNA-PKcs, we screened the specific DNA-PKc inhibitor KU60648 (IC 50 =19nM, (15) ) against a panel of 94 genomically well-annotated cancer cell lines (Suppl. Table 1 ), which covered a broad spectrum of cancer entities, histological subtypes (Suppl. Fig. 1A , inset) and cancer-associated genomic aberrations ( Fig. 1 A, B) . We used the Brd4Nut-fused cell line HCC2429 as a positive control (Fig. 1A , Suppl. Table   1 ), for which we had recognized addiction to DNA-PKcs in follow-up experiments of a previous study (14) . Conversely, A375 and A549 cells, which we had previously shown to be resistant against the DNA-PKcs inhibitor KU60648, were included to benchmark DNA-PKcs independence (14 (Fig. 1B) . Specifically, frameshift mutations in MLL3 (encoding the PTIP-interacting protein MLL3) (p=9.32x10 -4 ) were identified as significant predictors for non-oncogene addiction to the NHEJ kinase DNA-PKcs. Furthermore, mutations in ATM and BRCA1 were also associated with KU60648 sensitivity (Suppl. Fig. 2 ). While displaying strong effects (GI 50 ratio 3.5), these associations did not meet significance criteria, either due to the low mutation frequency of these genes in the examined cancer lines (e.g. BRCA1, n = 3) or due to dissimilar effects on compound activity depending on the respective mutation type (e.g. ATM); exclusively frameshift mutations of the latter co-clustered significantly with compound activity (Suppl. Fig. 2 ). In agreement with our initial hypothesis, a gene ontology-based analysis (23) revealed that disabling mutations in DNA repair genes were significantly (p=2.98 x 10 -12 ) enriched in DNA-PKcs inhibitor-sensitive cell lines (Fig. 1A, inset ). In particular, we observed an accumulation of HR genes, for which mutations were significantly associated with KU60648 sensitivity. The initial steps of the HR pathway can be arbitrarily clustered into three distinct processes, namely focus nucleation, DSB resection and Rad51 loading (Fig. 1C) ; our screen revealed mutations in critical components in all of them (Fig. 1C) . These data suggest that HR deficiency in general represents a cancer-associated condition that displays synthetic lethality with the NHEJ kinase DNA-PKcs.
To our surprise, mutations in the mismatch repair gene MSH3 (p=9.53x10 -4 ) emerged amongst the most significant predictors of compound activity ( to protein structure-damaging micro-deletions in the two longest mono-/ trinucleotide repeat sequences of the MSH3 coding sequence (Fig. 1A , B, Suppl. Fig. 2, 3A) . Intriguingly, frameshift mutations in A 8 stretches occur frequently as somatic alterations of MSH3 in microsatellite-instable colorectal cancer (24) (25) (26) (27) . Concordantly, we detected such mutations in our cancer cell line panel; 10 out of 67 cell lines displayed micro-deletions in the two longest mono-/ trinucleotide repeat sequences ( Figure 1A , Suppl. Fig. 3A) . Together, our observations strongly suggest that DNA-PKcs inhibition might emerge as a novel therapeutic principle for the targeted treatment of MSH3-defective cancer.
In our initial screen, we noticed that only two of a total of three BRCA1-mutant cell lines were classified as KU60648-sensitive (H1838, H1563). To molecularly dissect this diverse pattern of compound sensitivity, we subjected the BRCA1 mut cell lines H2347, H1563, H1838 to Sanger sequencing of all 23 BRCA1 exons (Suppl. Fig. S3B , C, D) and found that only the H1563 cell line carried homozygous BRCA1 mutations. Intriguingly, KU60648-sensitive H1838 cells did not show homozygous BRCA1 mutations. However, they carried an MSH3 mutation (Fig. 1A) , which likely rationalizes their KU60648 sensitivity.
DNA-PKcs inhibition induces apoptosis in MSH3-mutant cells
CTG assays revealed that MSH3-mutant cell lines displayed a robust DNAPKcs inhibitor response (p max = 7.81x10 -6 , t-test) (Suppl. To further validate KU60648-induced apoptosis with an independent assay, we used flow cytometry ( and BRCA1-defective cell lines (Fig. 2C, D, Suppl. Fig. 6, 7, 8 ). We used RNA-interference (RNAi) to deplete DNA-PKcs in four sensitive and two resistant control lines (Fig. 2C) . Knockdown efficiency was confirmed by immunoblotting (Suppl. Fig. 6 ). Confirming that repression of DNA-PKcs expression, leads to the induction of apoptosis in MSH3-mutant settings, we reproducibly detected cleavage of caspase-3 in KU60648-sensitive cell lines (HCC44, HCC2429), 120 hours following viral shRNA delivery (Suppl. Fig. 6 ).
Next, we assessed the effects of RNAi-mediated repression of PRKDC in colony formation assays (Fig. 2C) . Two weeks after viral RNAi delivery, we observed complete eradication of KU60648-sensitive HCC44, H1703, HCC2429, and H1563 lines, whereas KU60648-resistant H1568 and HCC1359 lines did not exhibit any signs of morphological change (Fig. 2C) Fig. 7A ), in order to choose two shRNAs (shXRCC5 #1, shXRCC5 #3), which effectively silenced expression of Ku80.
In colony formation assays, we observed mild growth-arrestive effects of Ku80 depletion in the MSH3-proficient cell lines, indicating that Ku80 is critical for cell survival in general (Suppl. Fig. 7B, C) . In contrast, strong cytotoxic effects were detected in MSH3-deficient cells for both constructs targeting Ku80 (Suppl. Fig. 7B, C) . Therefore, shRNA-mediated suppression of an independent NHEJ protein had similar cytotoxic effects in MSH3-deficient cells as knockdown of PRKDC.
Next, we compared the KU60648 response of Msh3-proficient and -deficient murine embryonic fibroblasts (MEFs) to validate Msh3 deficiency as a genetic determinant of DNA-PKcs addiction (Suppl. Fig 8A) . In brief, we first assessed (Fig. 2D, Suppl. Fig. 8C ). Together, genetic repression of PRKDC in MSH3-mutant cells on the one hand (Fig. 2C , Suppl.
Research. (Fig. 2D, Suppl. Fig. 8 ) cross-validated the proposed synthetic lethal interaction between these two genes. Further, the cytotoxic effects, which we observed in MSH3-mutant cells under suppression of Ku80 expression (Suppl. Fig. 7 ), might suggest a generalizable synthetic lethal interaction between the HR and NHEJ pathways.
MSH3-defective cell lines display a defect in homologous recombination-based DSB repair
Our initial screen revealed that alterations in HR-mediated DSB repair are associated with DNA-PKcs inhibitor sensitivity (Fig. 1, Suppl. Fig. 1, 2) . Thus, we next asked whether HR defects were responsible for the DNA-PKcs addiction that we observed in MSH3-mutant cells. To this end, we transiently shown to result in severely impaired HR-mediated DSB repair (7, 11), we also studied the BRCA1-mutant H1563 cell line (Fig. 3, Suppl. Fig. 9A ).
To examine the DSB repair kinetics in our cell line panel, we used indirect immunofluorescence to monitor the persistence of etoposide-induced γH2AX nuclear foci as an established marker for unrepaired DSBs (1). We observed robust formation of γH2AX nuclear foci in all cell lines that were analyzed 4 hr following removal of etoposide (Fig. 3A, B , Suppl. Fig. 9A ), whereas no
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-16 -nuclear γH2AX foci could be detected in untreated cells. However, 72 hr after etoposide removal, these foci had disappeared in all cell lines (Fig. 3A, B and Suppl. Fig. 9A ), suggesting that both MSH3-proficient and -defective, as well as BRCA1-mutant cells were capable of repairing etoposide-induced DSBs.
In a parallel set of experiments, we stained these cells with an antibody detecting Rad51 nuclear foci (Fig. 3A, C and Suppl. Fig. 9A ), which are a hallmark feature of ongoing HR-mediated DSB repair (11). Of note, BRCA1-deficient cells were previously shown to lack Rad51 foci formation in response to DSB-inducing agents (7, 11) . As shown in Fig. 3 and Suppl. ) (Fig. 3A , C, Suppl. Fig. 9A ). These data strongly suggest that the HR-mediated repair of etoposide-induced DSBs is substantially impaired in MSH3-mutant cells. Similar effects have been previously described for BRCA1-deficiency (Fig. 3A, C and (11) ).
HR-deficiency rationalizes the synthetic lethality between MSH3 and
PRKDC
Given the substantial HR defect that we had observed in MSH3-mutant cells (Fig. 3 , Suppl. Fig. 9A ), we next hypothesized that pharmacological NHEJ 
MEFs and H1563
[BRCA1mut]) cells by applying an etoposide pulse (0.1μM, 1hr) in the absence or continued presence of 0.5μM KU60648. Cells were protected from premature apoptosis by addition of the irreversible pan-caspase inhibitor Z-VAD (10 μM), which was applied together with etoposide. Similar to the experiments detailed in Figure 3 , we performed immunofluorescence to detect nuclear γH2AX and Rad51 foci (Fig. 4 , Suppl. (Fig. 1, 2 (Fig. 5A-E , Suppl. Fig. 10A-F (Fig. 5A -E, Suppl. Fig. 10A -F).
As described previously (14), we administered 40mg/kg doses of the DNAPKcs inhibitor KU60648 twice daily (intraperitoneal injection). Intriguingly, we observed a substantial (final tumor volume: 31.5%) and significant (p = 3.1x10 -4 ) (Fig. 5A , Suppl. Fig. 10A , E) tumor volume shrinkage for HCT116-driven tumors under KU60648 therapy within 14 days, whereas A549 control tumors were completely resistant and even showed continued volume gains under KU60648 therapy (Fig. 5B , Suppl. Fig. 10B, F) . In order to further compare the tumor proliferation rate between both therapy groups, we stained tumor samples with Ki67-specific antibodies after 14-day therapy (Fig. 5E ).
Shrinkage of HCT116 tumors translated into complete eradication of the Ki67-positive cell fraction under KU60648 therapy. In marked contrast, the Ki67 staining of A549 tumors remained stable between control and therapy groups, indicating their maintained proliferation under therapy (Fig. 5E ).
Tumors driven by MYC/HRAS G12V double-transduced MEFs displayed a more aggressive phenotype than the HCT116/A549-driven tumors (Fig. 5 C, D, Suppl. Fig. 10C, D) . Thus, tumor volumes could only be followed for seven days before control animals had to be sacrificed. In spite of this highly aggressive growth behavior, therapy with KU60648 resulted in stable disease (final tumor volume: 109%) of Msh3 -/-MEF-driven lesions, while we did not observe any significant therapeutic effect of KU60648 on Msh3 wt/wt MEFdriven tumors (Fig. 5C , D, Suppl. Fig. 10C, D) . In summary, our results strongly recommend DNA-PKcs as a promising drug target for rational design 
Discussion
Alterations in HR signaling are associated with DNA-PKcs addiction
Eukaryotic cells have evolved a plethora of DNA repair pathways, which together function to maintain genomic integrity of multicellular organisms (2).
Perhaps not surprisingly, inactivating mutations in these DNA repair pathways are commonly observed in human tumors and are thought to fuel a 'mutator phenotype' (33) (34) (35) . For instance, cancer genome re-sequencing data suggest that ~50% of high-grade serous ovarian carcinomas are HR-defective (36).
We have previously reported an actionable synthetic lethal interaction between the HR gene ATM and the critical NHEJ gene PRKDC (13, 14, 37) .
In addition, the combined knockout of ATM and PRKDC was recently shown to result in embryonic lethality at E7.5 in mice (12) . Intriguingly, E7.5 is a developmental stage at which embryonic cells are hypersensitive to DNA damage (12) . Based on these observations, we hypothesized that mutations in additional HR genes might be associated with a similar DNA-PKcs addiction.
In order to systematically decipher additional genetic aberrations that are associated with DNA-PKcs addiction, we first linked large-scale sequencing data (16) to high-throughput KU60648 activity profiling across 67 cancer cell (Fig. 1) . As reported recently (38) , potency and selectivity of several compounds are underestimated, if analysis is restricted to their half maximal growth inhibitory concentrations (GI 50 ). Hence, we amended our interpretation of the cell line screen by Hill's coefficients and nearest-neighbor distances (Suppl. Fig. 1 ). Using this approach, we found that mutations in genes involved in DNA repair (p = 2.98 x 10 -12 ) significantly associated with KU60648 sensitivity. More precisely, we were able to confirm mutations in several genes with a known role in HR-mediated DSB repair, including
BRCA1, BRCA2, ATM, CHEK2, RAD50, SMC2
and PAXIP, to predict DNAPKcs addiction (Fig. 1 , Suppl. Fig. 2) . Intriguingly, the therapeutic response of HR-defective cancer cells to KU60648 appeared to be independent of TP53 mutation status (Fig. 1A) . This observation strongly suggests that DNA-PKcs inhibition in HR-defective tumors might be a viable therapeutic strategy to selectively target TP53-defective lesions, which are typically resistant against most frontline anticancer agents, such as chemo-and radiation therapy.
To our surprise, we identified MSH3 as a strong determinant for KU60648 sensitivity, which we showed to be involved in HR-mediated DSB repair in follow-up experiments ( Fig. 1-4 ). There is accumulating circumstantial evidence suggesting a role for the Msh2/Msh3 complex in DSB repair (39-43).
For instance, RNAi-mediated MSH3 depletion has recently been shown to result in substantially delayed Rad51 loading after 2Gy ionizing radiation (25).
Here, we demonstrate that MSH3 mutation or deficiency is associated with an HR defect due to impaired Rad51 loading (Fig. 3) . More importantly, we link this MSH3-deficiency-associated HR defect to a druggable DNA-PKcs addiction in vitro (Fig. 2 ) and in vivo (Fig. 5) .
Therapeutically targeting the synthetic lethal interaction between MSH3
and PRKDC We genetically validated the synthetic lethal interaction between MSH3 and PRKDC that emerged from our initial screen (Fig. 2) . To this end, we showed that pharmacological DNA-PKcs inhibition in Msh3 knockout MEFs resulted in the induction of massive apoptosis, compared to Msh3-proficient isogenic control cells. Conversely, RNAi-mediated repression of PRKDC resulted in apoptotic demise of MSH3-mutant cancer cells, while MSH3-proficient control cells were largely unaffected by PRKDC knockdown (Fig. 2, 6) .
Functionally, we demonstrate that Msh3 knockout results in substantially impaired HR-mediated DSB repair due to delayed Rad51 loading (Fig. 3) .
However, MSH3-deficiency did not completely abrogate etoposide-induced DSB repair. In fact, MSH3-defective cells remained capable of repairing etoposide-induced genotoxic lesions, likely through recruitment of alternative DSB repair pathways, such as NHEJ (Fig. 3, 6 ). However, pharmacological inhibition of the essential NHEJ kinase DNA-PKcs completely prevented etoposide-induced DSB repair and led to the generation of ssDNA repair intermediates, which have previously been shown to represent a chromatin structure that triggers apoptosis (6, 14, 44) . Moreover, we observed early loss of S-phase for all cell lines under KU60648 treatment (Suppl. Fig. 4) .
However, only KU60648-resistant cells were able to repair KU60648-induced DNA damage and returned to normal cell cycle profiles within 48 hr. Together, these observations mechanistically rationalized the massive induction of apoptosis that we detected by immunoblotting and flow cytometry (Fig. 2) .
Clinical Perspective
Our data reported here strongly suggest that the synthetic lethal interaction between the NHEJ kinase DNA-PKcs and multiple HR genes, including BRCA1, BRCA2, ATM, CHEK2, RAD50, SMC2 and PAXIP, might be therapeutically exploited in patients with HR-defective neoplastic disease. 
Materials and methods
Cell lines and reagents
All human cell lines were obtained from ATCC (www.atcc.org) and cultured in RPMI or DMEM media, supplemented with 10% of FCS at 37°C in a humidified incubator supplied with 5% CO 2 . Their identity was authenticated by genotyping (SNP 6.0 arrays, Affymetrix) and all cell lines were tested for infection with mycoplasma (MycoAlert, Lonza).
Compounds were purchased from Axon Medchem (KU60648) or Sigma Aldrich (etoposide, doxorubicin), dissolved in water or DMSO and stored as aliquots at -80°C or -20°C. Two independent lots were tested for each compound.
Retroviral packaging constructs pMDg and pMDg/p were a kind gift from T. 
Genetic compound activity prediction
For calculation of GI 50 , concentration-viability curves were interpolated by logistic functions (R package "ic50" (48)). For each concentration (range:
150nM -1μM) we calculated the distance to its nearest neighbor in the KU60648 screening activity profile, in order to infer a suitable GI 50 threshold.
We used this threshold to classify cells into KU60648-sensitive and -resistant lines.
We next annotated all cell lines, for which sequencing data were available in the CCLE database (16) (MAF files), by its protein coding mutations. We tested for each gene whether mutations were more frequent in the KU60648-sensitive cohort than in the group of resistant cell lines by Fisher's exact test.
Additionally, we calculated for each gene its sensitivity effect by comparing GI 50 values between mutant vs. wildtype cell lines. For missense mutations, we predicted their functional effect on global protein structure by PolyPhen-2 algorithm (49).
Xenograft mouse models
All animal procedures were approved by the local animal protection committee and the local authorities. 6-10 week old male NMRI nu/nu mice (CRL:NMRI-FOXN1 NU, Charles River) were subcutaneously engrafted with A. DNA double-strand break repair kinetics were monitored (0hrs, 4hrs, 72hrs) after short (1hr) exposure to a low-dose (0.1μM) etoposide pulse.
Representative immunofluorescence images (green: γ-H2AX or Rad51 Box plot diagrams display quantification of γ-H2AX stains for the experiment shown in A. in 9 independent cancer cell lines. Significance values were derived from comparing γ-H2AX foci pos cell counts (4hrs) by t-testing, n=3. C.
Box plot diagrams representing the quantification of Rad51 foci for the experiment shown in A. in 9 independent cancer cell lines. Significance levels were determined by t-test, n=3. 
